Tomas Landh is since Nov 2014 R&D Innovation Sourcing VP. He was previously Director Strategy and Innovation Sourcing at Novo Nordisk, Diabetes Research. Tomas joined Novo Nordisk in 2003.
Tomas is currently responsible for the scouting and coordination of evaluation of external innovation regarding all aspects of diabetes, including insulins, GLP1’s and new molecular formats and modalities. He works closely with the teams responsible for assessing innovation in the other therapy areas of Novo Nordisk, obesity, NASH, CVD and haemophilia. Besides innovative therapies, the Innovation Sourcing team at Novo Nordisk is responsible for the sourcing and evaluation of a broad range of technologies, including new drug delivery systems and protein engineering means. In addition to seeking external innovation in these areas, Tomas is involved in developing new strategic modes of accessing innovation in general.
Tomas has more than 25 years of experience of all stages of drug development and delivery, ranging from academia, small businesses, foundations and big pharma/biotech. He received his PhD in Biophysical Engineering from Lund’s Institute of Technology and has authored a number of scientific papers and book chapters on cell membrane morphologies, pharmaceutical formulations, and holds a number of patents. Tomas has served on a number of SAB’s for biotech’s and is currently an international advisor to LARTA/ NIH- and NSF-CAP programs.